Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.40 |
| ▸ | PLK1 | P53350 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908960 | 0.89 | L3MBTL1 (0.44) | L3MBTL1POLBALDH1A1KDM4EBRD4 | |
| SCHEMBL23909115 | 0.81 | KDM4E (0.41) | L3MBTL1POLBALDH1A1KDM4ELMNA | |
| SCHEMBL18171832 | 0.75 | KDM4E (0.48) | POLBALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL5956307 | 0.75 | GAA (0.54) | CDC25AL3MBTL1POLBALDH1A1KDM4E | |
| SCHEMBL23909094 | 0.74 | MAPT (0.64) | L3MBTL1POLBALDH1A1MAPT | |
| SCHEMBL30684924 | 0.74 | PLK1 (0.50) | L3MBTL1MCL1PLK1POLBALDH1A1 | |
| SCHEMBL15076008 | 0.74 | KDM4E (0.63) | ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL1520396 | 0.72 | BRD4 (0.54) | CDC25AL3MBTL1POLBMAPTBRD4 | |
| SCHEMBL2882457 | 0.70 | L3MBTL1 (0.73) | CDC25AL3MBTL1MCL1PLK1ALDH1A1 | |
| SCHEMBL16099676 | 0.70 | ALDH1A1 (0.58) | L3MBTL1POLBALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | CDC25A 1021/4885L3MBTL1 2938/4885MCL1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.